Bioscience Americas ...Solutions for a Healthier World.
Innovating to Bring Important New Therapies to Patients
Bioscience Americas purpose is to innovate to bring therapies that significantly improve patients’ lives. R&D is at the heart of fulfilling Bioscience Americas purpose as we work to translate advanced science and technologies into the therapies that matter most.
Today, we are at a unique moment in biomedical innovation. More than a decade after the decoding of the human genome, we have a fundamentally better understanding of human biology and what causes disease. We have also learned that it takes more than just great science to deliver meaningful new therapies. Over the last few years, Bioscience Americas has taken a hard look at the way we did R&D in the past. We have better integrated science and business, which meant transforming our approach to be more collaborative, more focused, and, we believe, more powerful for patients. Ultimately, we’ve worked to design an engine that can deliver patients a sustainable flow of important new therapies and treatment protocols, year after year.
We focus our efforts in core areas where we believe Bioscience Americas is best positioned to bring unique, needed therapies to patients. We bring to these areas, cutting-edge capabilities in stem cell and immunological design and development.
Key to our approach is collaborating in new and dynamic ways with other innovators across the health landscape including academic scientists, patient foundations, governments, other biotech companies and treating physicians.
Today our pipeline is comprised of several innovative therapies including potentially first-in-class stem cell protocols, ground breaking therapy for lupus and diabetes and the next-generation of targeted therapies for cancer. We are also building upon a heritage of developing safe and effective regenerative therapies to introduce high-quality preventative medicine that can broaden patient access with lower-cost alternative therapies.
We invite you to learn more.